Let's get more now on the story. Pharma and biotech reporter Anukica Kim Constantino. Anukica, what's the story here.Is this pill going to be ready soon. >> Right. So, thanks for having me on today.So, basically the news today is that Lily has trial data showing that its obesity pill could be an effective maintenance treatment for people that want to preserve their weight loss but don't want to keep taking weekly injections like Wgoian Zepbound. So in this trial, they basically followed people that initiall ...

Let's get more now on the story. Pharma and biotech reporter Anukica Kim Constantino. Anukica, what's the story here.Is this pill going to be ready soon. >> Right. So, thanks for having me on today.So, basically the news today is that Lily has trial data showing that its obesity pill could be an effective maintenance treatment for people that want to preserve their weight loss but don't want to keep taking weekly injections like Wgoian Zepbound. So in this trial, they basically followed people that initiall ...

Core Viewpoint - Zhejiang Hai Zheng Pharmaceutical Co., Ltd. has received a new veterinary drug registration certificate for its product, Methylprednisolone Tablets (for dogs), which is classified as a Category V new veterinary drug, indicating compliance with relevant regulations and enhancing the company's strategic positioning in the veterinary medicine sector [1][4]. Group 1: New Veterinary Drug Information - The new veterinary drug is named Methylprednisolone Tablets (for dogs) and has been approved as a Category V new veterinary drug [1]. - The registration certificate number for the new veterinary drug is (2025) New Veterinary Drug Certificate No. 129 [1]. - The drug is developed by Zhejiang Hai Zheng Animal Health Products Co., Ltd. in collaboration with seven other companies [1]. Group 2: Drug Application and Use - Methylprednisolone Tablets (for dogs) are intended for the treatment of canine inflammatory and allergic diseases, and can be part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears [1]. - The drug is effective for various inflammatory/allergic diseases that can be treated with glucocorticoids, including immune-mediated diseases [1]. Group 3: Market Position and Future Outlook - The approval of Methylprednisolone Tablets (for dogs) is expected to enhance the company's market competitiveness in the veterinary drug sector [4]. - The product is now ready for production and market launch, pending the acquisition of the veterinary product approval number, although it is noted that it will not have a significant short-term impact on the company's performance [4].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Viewpoint - Athira Pharma Inc. is making significant strides in its development pipeline by acquiring rights to lasofoxifene, a drug in a Phase 3 trial for metastatic breast cancer, which is expected to enhance its market position and growth potential [1][2]. Group 1: Acquisition Details - Athira has secured an exclusive global license (excluding Asia and certain Middle Eastern countries) from Sermonix Pharmaceuticals for the development and commercialization of lasofoxifene [2]. - As part of the agreement, Athira will issue a pre-funded warrant to purchase approximately 5.5 million shares at an exercise price of $0.001 per share, along with potential payments of up to $100 million based on commercialization or annual net sales milestones [3]. Group 2: Financing and Development Plans - The company announced a $90 million upfront financing through private placement of common stock and warrants, which could provide an additional $146 million if the warrants are exercised, aimed at supporting the development of lasofoxifene through key clinical and regulatory milestones [4]. - The net proceeds from the financing will be utilized for the development of lasofoxifene for treatment-resistant metastatic breast cancer, other clinical assets, and general corporate purposes [5]. Group 3: Market Performance - Following the announcement, Athira Pharma's stock surged by 74.49% to $7.22, reaching a new 52-week high, indicating strong market confidence in the company's future prospects [5].

Key Points Invest in stocks with good fundamentals, solid growth prospects, and steady dividends. These blue chip stocks have strong businesses that generate consistently strong results. With exposure to healthcare and oil and gas, they can also help diversify your portfolio. 10 stocks we like better than AbbVie › Is the S&P 500 due for a crash next year? That's a big question on the minds of many investors these days. Concerns about bubbles in tech and overall high valuations for the stock mark ...

Core Insights - Johnson & Johnson (JNJ) has received FDA approval for the subcutaneous formulation of its EGFR/MET inhibitor, Rybrevant, now branded as Rybrevant Faspro, which is approved for all indications of the intravenous version [1][8] - The subcutaneous version offers improved patient convenience, reducing administration time from up to an hour for IV to as little as five minutes for SC [3][8] - JNJ aims to compete more effectively against AstraZeneca's Tagrisso, the current standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) [4] Drug Approval and Efficacy - Both Rybrevant formulations are approved for treating non-small cell lung cancer (NSCLC) across four indications [2] - The FDA's approval was supported by data from the late-stage PALOMA-3 study, demonstrating that Rybrevant Faspro is at least as effective as the IV formulation [5][8] - The SC version utilizes Halozyme Therapeutics' proprietary drug delivery technology [6] Market Performance and Sales Goals - JNJ's stock has increased over 45% this year, outperforming the industry growth of 16% [7] - The oncology segment accounts for approximately 27% of JNJ's total revenues, with oncology sales rising nearly 21% year-over-year to $18.52 billion in the first nine months [10] - JNJ has set an ambitious target to achieve $50 billion in oncology sales by the end of the decade, needing to more than double sales from 2024 levels [12][13] Strategic Growth Initiatives - The company is expanding its oncology pipeline through acquisitions, including a recent agreement to acquire Halda Therapeutics for $3.05 billion, focusing on prostate cancer [14]

Core Viewpoint - Athira Pharma announced transformative transactions in a press release, which were discussed during the conference call [2][3]. Group 1: Company Overview - The conference call featured key executives including Dr. Mark Litton (President and CEO), Dr. Javier San Martin (Chief Medical Officer), Dr. Kevin Church (Chief Scientific Officer), Robert Renninger (Chief Financial Officer), and Dr. David Portman (Founder and CEO of Sermonix) [2]. Group 2: Financial and Operational Insights - The call included forward-looking statements regarding the company's future clinical development activities, financial condition, and operating performance, which are based on management's current beliefs and expectations [4].

Company Overview - TAE Technologies, a nuclear fusion developer, is merging with Trump Media & Technology Group in a $6 billion deal, marking a significant milestone for the fusion energy sector amid rising electricity demand from AI data centers [3][4] - TAE has over two decades of experience in nuclear fusion, aiming to provide abundant, carbon-free power, and is backed by major investors including Alphabet, Chevron, and Goldman Sachs [4] Technological Advancements - TAE has made significant advancements in reactor design, reducing costs and complexity, which are crucial for commercial viability [5] - The company plans to deploy fusion plants capable of producing between 350 and 500 megawatts each [5] Market Context - The merger is seen as a major investment in nuclear fusion power, especially in the context of the ongoing AI Arms Race [5] - The stock market is experiencing volatility, with Micron's strong guidance positively impacting AI-related stocks [5] Inflation and Economic Indicators - The annual headline Consumer Price Index (CPI) fell to 2.7%, below the 3.1% consensus, while core CPI decreased to 2.6% against a forecast of 3% [6] - Analysts caution that the data may not accurately reflect true inflation trends due to assumptions made by the Bureau of Labor Statistics [6][7] Other Notable Developments - OpenAI is in preliminary discussions to raise up to $100 billion at a valuation of around $750 billion, representing a 50% increase from its previous valuation [10] - Meta's outgoing AI scientist is seeking €500 million for a new startup, valuing it at approximately €3 billion [10]

PRESS RELEASE AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm. Maxim Group began covering the stock with a study entitled “Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS” ...